CDK12 inhibition reduces abnormalities in cells from patients with myotonic dystrophy and in a mouse model.

Autor: Ketley A; School of Life Sciences, University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK., Wojciechowska M; School of Life Sciences, University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK., Ghidelli-Disse S; Cellzome GmbH, Molecular Discovery Research, GlaxoSmithKline, Meyerhofstrasse 1, 61997 Heidelberg, Germany., Bamborough P; Computational and Modelling Sciences, GlaxoSmithKline, Medicines Research Centre, Hertfordshire SG1 2NY, UK., Ghosh TK; School of Life Sciences, University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK., Morato ML; School of Life Sciences, University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK., Sedehizadeh S; School of Life Sciences, University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK., Malik NA; School of Life Sciences, University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK., Tang Z; Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642-0001, USA., Powalowska P; School of Life Sciences, University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK.; School of Chemistry, University of Nottingham, University Park, Nottingham NG7 2RD, UK., Tanner M; Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642-0001, USA., Billeter-Clark R; School of Life Sciences, University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK., Trueman RC; School of Life Sciences, University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK., Geiszler PC; School of Life Sciences, University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK., Agostini A; School of Life Sciences, University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK., Othman O; School of Life Sciences, University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK., Bösche M; Cellzome GmbH, Molecular Discovery Research, GlaxoSmithKline, Meyerhofstrasse 1, 61997 Heidelberg, Germany., Bantscheff M; Cellzome GmbH, Molecular Discovery Research, GlaxoSmithKline, Meyerhofstrasse 1, 61997 Heidelberg, Germany., Rüdiger M; Screening Profiling and Mechanistic Biology, GlaxoSmithKline, Medicines Research Centre, Hertfordshire SG1 2NY, UK., Mossakowska DE; Discovery Partnerships with Academia, GlaxoSmithKline, Medicines Research Centre, Hertfordshire SG1 2NY, UK.; Malopolska Centre of Biotechnology, Jagiellonian University, 30-348 Krakow, Poland., Drewry DH; Department of Chemical Biology, GlaxoSmithKline, Research Triangle Park, NC 27709-3398, USA., Zuercher WJ; Department of Chemical Biology, GlaxoSmithKline, Research Triangle Park, NC 27709-3398, USA.; SGC Center for Chemical Biology, UNC, Eshelman School of Pharmacy, Chapel Hill, NC 27599, USA., Thornton CA; Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642-0001, USA., Drewes G; Cellzome GmbH, Molecular Discovery Research, GlaxoSmithKline, Meyerhofstrasse 1, 61997 Heidelberg, Germany., Uings I; Discovery Partnerships with Academia, GlaxoSmithKline, Medicines Research Centre, Hertfordshire SG1 2NY, UK., Hayes CJ; School of Chemistry, University of Nottingham, University Park, Nottingham NG7 2RD, UK., Brook JD; School of Life Sciences, University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK. david.brook@nottingham.ac.uk.

Publikováno v: Science translational medicine [Sci Transl Med] 2020 Apr 29; Vol. 12 (541).